Alex Biese

The FDA has approved Enhertu and Perjeta for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.

This guide features information from diagnosis to treatment of adenocarcinoma of the bladder.

For AYA breast cancer survivors, mobile health intervention was associated with improvements to general and cancer-specific quality of life.

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Among children receiving chemotherapy for acute lymphoblastic leukemia, 30% of their families developed catastrophic financial toxicity.

The FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who received at least two prior lines of systemic therapy.

As part of her journey with stage 3 inflammatory breast cancer, Lindsey Gunter experienced chemotherapy side effects so severe that she was unable to walk.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

CURE recently sat down with an expert to discuss crucial information for patients with gastrointestinal stromal tumors, or GISTs.

Among young patients, clinical trial results have shown that Pedmark is associated with a reduction in chemotherapy-induced ear damage.

Breaking down what patients need to know about penile cancer, from diagnosis to treatment.

CURE discussed the regional anesthesia technique known as PEC I and II blocks with breast surgeon Dr. Christopher M. McGreevy.

Research is underway for an experimental treatment for patients with succinate dehydrogenase deficient gastrointestinal stromal tumors.

After more than 30 years since she was first diagnosed with a myeloproliferative neoplasm, Nona Baker is hopeful for the future thanks to current clinical trial landscape.

Immunotherapies have represented a revolution in the landscape of cancer treatment — and may have a crucial partner in the form of personalized cancer vaccines.

The FDA approved Imfinzi with chemotherapy for adults with resectable gastric or gastroesophageal junction adenocarcinoma.

From diagnosis to treatment, here is what patients need to know about squamous cell carcinoma of the bladder.

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

In a recent interview with CURE, Nona Baker shared insights from her blood cancer journey that began more than 30 years ago.

Nona Baker received a diagnosis of essential thrombocythemia in 1991, followed by polycythemia vera in 2004.

Dr. Ajay Gupta sat down with CURE to explain the basics of gastrointestinal stromal tumors, highlighting what patients with this disease need to know.

Dr. Benjamin Herzberg spotlighted some of the “weird and wacky” new ideas in the field of targeted therapies for the treatment of lung cancer.

The FDA has granted fast track designation to ITM-94 as a diagnostic agent for the detection of the most common type of kidney cancer.

The FDA has approved Epkinly plus Revlimid and Rituxan for the treatment of patients with relapsed or refractory follicular lymphoma.

For U.S. Marine Corps veteran and devout marathon runner Hank Donigan, not even a diagnosis of brain cancer could slow him down.

Breaking down the rare gastrointestinal cancer, from diagnosis to treatment.

American Indian and Alaskan Native individuals face some of the highest kidney cancer burdens in the United States.

The FDA approved Komzifti in relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.